JD.com Receives Drug Sales Certification From China FDA

JD.Com Inc (ADR) (NASDAQ: JD) received "Grade A Online Drug Sales Platform" certification from China's State Food and Drug Administration, according to Marbridge Consulting.

“The platform is the third to receive the "Grade A" certificate alongside Alibaba Group Holding Inc's (NYSE: BABA) B2C e-commerce site Tmall and Chinese B2C online retailer Yihaodian.”

The report noted that “JD.com previously focused its energies on the sale of healthcare products which did not require licenses. In 2014 the website section entitled "Healthcare" was renamed "Healthcare and Medical Treatment" in anticipation of making online drug sales.”

Marbridge commented that in “September 2014 the firm achieved RMB 66 million in online drug sales, and sales on China's annual November 11 "Singles Day" e-commerce shopping holiday grew 315 percent from the previous year.”

JD.com recently traded at $24.55, down 0.24 percent.